MediCrops Holding AG is an internationally operating pharmaceutical company headquartered in Pfäffikon (SZ) with his sister company MediCrops Biomedical Technologies AG, a Production and Manufacturing Site located in Yverdon-les-Bains (VD), Switzerland. We are specializing in the R&D, Production of standardized Cannabis Herbal Substance and Manufacturing of standardized Cannabis Herbal Preparation (APIs) containing THC and other cannabinoids/terpenes. We are aiming to harness the full medicinal potential of the cannabis plant and make it available to patients around the world as a therapeutic agent. We strongly believe in an operating philosophy based on continuous improvement, on openness in communication, integrity in serving our consumers, fairness and concern for our employees and responsibility to the communities within which we operate.

While over 100 cannabinoids are found in the hemp plant, only two molecules (THC and CBD) have been studied in detail. With our R&D team we aim to exploit the full medicinal potential of the cannabis plant, working also on terpenoids that can increase the THC bioavailability in human organism, using molecular biology, phytochemistry, “omics” and breeding.